Form 4: Metsera Executive Disposes Shares Post-Pfizer Merger

Clive Meanwell, Executive Chairman of Metsera, Inc., reported the disposition of all his Metsera securities following the company's acquisition by Pfizer Inc.

Summary

• Clive Meanwell, Executive Chairman and Director of Metsera, Inc., reported the disposition of all his direct and indirect beneficial ownership in Metsera, Inc. securities.
• These transactions occurred on November 13, 2025, as a direct result of the merger where Metsera, Inc. became a wholly-owned subsidiary of Pfizer Inc.
• Each outstanding share of Metsera common stock was converted into $65.60 in cash and one contractual contingent value right (CVR).
• Outstanding stock options were cancelled in exchange for cash (Closing Amount minus exercise price per share) and one CVR per share, with unvested portions subject to continued service and vesting on the first anniversary of the merger.
• Restricted Stock Units (RSUs) were cancelled and converted into cash ($65.60 per share) and CVRs, with no further vesting requirements.
• Meanwell disposed of 5,375 shares of common stock directly and 12,767,462 shares indirectly held through Population Health Partners, L.P. and Population Health GP LLC.
• He also disposed of 5,375 Restricted Stock Units, 32,250 stock options with an exercise price of $29.25, and 297,907 stock options with an exercise price of $8.18.

Sentiment

Score: 7

Explanation: The filing reflects the successful completion of a merger, providing a clear exit for shareholders at a specified cash value plus contingent rights. This is generally positive for shareholders of the acquired company, though the insider transaction itself is a procedural report of this event.

Positives

• Shareholders received a cash payment of $65.60 per share, representing a clear realization of value from the merger.
• The inclusion of Contingent Value Rights (CVRs) provides shareholders with potential additional payments based on future milestones.
• The merger provides a strategic exit for Metsera, integrating its assets into a larger pharmaceutical company, Pfizer Inc.
• For the reporting person, the transactions represent the monetization of their equity holdings in Metsera.

Negatives

• Metsera, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Pfizer Inc.
• The value of CVRs is contingent and uncertain, dependent on future events and the achievement of specific milestones.
• Unvested stock options converted into cash and CVRs are subject to a continued service requirement with Pfizer or its subsidiaries for one year post-merger to fully vest.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specific, undisclosed milestones.
• Holders of unvested stock options who received cash and CVRs must maintain continued service with Pfizer Inc. or its subsidiaries for one year following the merger to fully vest these payments.
• The specific terms and conditions of the CVRs, including the milestones and potential payment amounts, are not detailed in this filing, introducing uncertainty regarding their ultimate value.

Future Outlook

Metsera, Inc. is now a wholly-owned subsidiary of Pfizer Inc., and its independent future outlook is absorbed into Pfizer's strategic plans. The future value for former Metsera shareholders holding CVRs is contingent upon the achievement of specified milestones.

Industry Context

This transaction is characteristic of the pharmaceutical and biotechnology industry, where larger companies like Pfizer acquire smaller firms to expand their pipeline, technology, or market presence. The use of Contingent Value Rights (CVRs) is a common mechanism in such acquisitions to bridge valuation gaps and share future risks or upsides related to developmental assets.

Comparison to Industry Standards

• The cash plus CVR structure is a common acquisition model in the biotech sector, often used when the acquired company has pipeline assets with uncertain future value, allowing the acquirer to defer some payment until specific milestones are met.
• The $65.60 per share cash component provides a definitive return, while the CVRs offer potential upside, similar to other biotech acquisitions such as Bristol-Myers Squibb's acquisition of Celgene or Merck's acquisition of Acceleron Pharma, which also included CVR components.

Related Party Transactions

• 12,639,787 shares of Common Stock are held of record by Population Health Partners, L.P. ('PHP LP') and 127,675 shares of Common Stock are held of record by Population Health GP LLC ('PHP GP LLC').
• PHP GP LLC, as the sole general partner of PHP LP, may be deemed to beneficially own the shares held by PHP LP.
• As a member of PHP GP LLC, the Reporting Person (Clive Meanwell) may be deemed to share the power to direct the disposition and vote of the PHP Shares.
• The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders of Metsera, Inc. received a cash payment of $65.60 per share and Contingent Value Rights (CVRs), realizing value from their investment.
• Employees holding unvested stock options are subject to a continued service requirement with Pfizer Inc. or its subsidiaries for one year post-merger to fully vest their cash payments and CVRs.

Next Steps

• Potential future payments to CVR holders upon the achievement of certain specified milestones.
• Continued service with Pfizer Inc. or its subsidiaries for one year post-merger for holders of unvested stock options to fully vest their cash payments and CVRs.

Key Dates

Keywords

Metsera, MTSR, Pfizer, Merger, Acquisition, Form 4, Insider Transaction, Beneficial Ownership, Clive Meanwell, Contingent Value Right, CVR, Stock Option, RSU, Equity Compensation